BIBiogen BIIB · NASDAQ
$250.69 -1.24% (-$3.15)
- Market cap
- $37.5B
- Enterprise value
- $44.6B
- P/E
- 44.9x
- Forward P/E
- 20.1x
- PEG
- -
- P/S
- 3.8x
- P/FCF
- 12.6x
- EV/EBITDA
- 26.7x
- ROIC
- 4.3%
- Bruto marža
- 67.7%
- Neto marža
- 8.4%
- Dividend yield
- -
- Payout ratio
- -
- Neto dolg/EBITDA
- 4.2x
- Beta
- 0.17
- Free float
- 99.2%
O podjetju
Biogen Inc. (BIIB) is an American biotechnology company specializing in the research, development, and production of therapies for neurological and neurodegenerative diseases. With a portfolio of products focused on treating multiple sclerosis, Alzheimer's disease, and other neurological disorders, Biogen is one of the leading players in the neurology field. The company is known for its emphasis on scientific research and innovation, enabling it to bring groundbreaking treatment options to patients with serious health conditions. Biogen also collaborates with academic institutions and other pharmaceutical companies to expand its research and development capabilities. Biogen Inc. (BIIB) shares could be suitable for investors looking for opportunities in the biotechnology sector with a focus on neurology and neurodegenerative disease research.
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Christopher A. Viehbacher
Employees
7,500
Headquarters
Cambridge
Vrednotenje
Je današnja cena primerna?
Rast in ocene
Ali podjetje raste in kaj sledi?
Donosnost in kakovost
Koliko prihodkov ostane in kako dobro podjetje uporablja kapital?
Finančno zdravje
Ali zmore svoj dolg?
Kapital in dividende
Kaj podjetje počne z zasluženim denarjem?
Analitiki
Kaj menijo strokovnjaki in ali se to spreminja?
Lastniki in insajderji
Kdo ima delnice in kaj počne vodstvo?
Segmenti
Kateri del podjetja raste?
Primerjava s konkurenco
Kako se primerja s podobnimi podjetji?
Cena in tveganje
Kako se delnica obnaša?
Izkazi
Vse številke